DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL

BACKGROUND: Genomic analyses of DIPG have been so far mostly performed on autopsy samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three targeted therapies (erlotinib, everolimus, dasatinib) based on three biomarkers (EGFR, PTEN and PDGFRA respectively), a systema...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Castel, David, Barret, Emilie, Picot, Stephanie, Plessier, Alexandre, Le Dret, Ludivine, Nysom, Karsten, Huybrechts, Sophie, Capolino, Perrine, Le Deley, Marie-Cecile, Vassal, Gilles, Puget, Stephanie, Varlet, Pascale, Grill, Jacques, Debily, Marie-Anne
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475015/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.036
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars